Sponsored company news and issuer-paid coverage. Wall Street Wire articles are paid promotional content; see each article’s disclaimer.
If a european licensing deal for an ALS drug commands €500M, one must wonder how much more NeuroSense’s seemingly superior ALS therapy could actually be worth? (NASDAQ: NRSN)
Silexion Therapeutics’ (NASDAQ: SLXN)* groundbreaking RNAi therapy showing 70-80% tumor reduction takes major step forward with global manufacturing collaboration; Wall Street analysts reportedly maintain $5 price target representing potential 500% upside as company targets $470B precision medicine market In a strategic move that significantly advances its revolutionary cancer treatment
Eli Lilly’s oral GLP-1 breakthrough has sparked even greater interest from the market in the innovative obesity drug sector. Companies like DarioHealth, which provides digital support tools to improve medication adherence, and Viking Therapeutics, with its own GLP-1 pipeline may present unique opportunities to benefit from the
Silexion Therapeutics Corp. (NASDAQ: SLXN)* recently released its full-year 2024 financial results and business update, showcasing remarkable progress in its clinical and preclinical programs targeting KRAS-driven cancers. Following these developments, we spoke with the Chief Financial Officer Mirit Horenshtein Hadar about the company’s achievements and strategic direction.
Actelis Networks (NASDAQ: ASNS)*, a leader in cyber-hardened networking solutions, continues to strengthen its position in the critical infrastructure sector with its recent announcement of a new order from one of North America’s largest railway groups to support Positive Train Control (PTC) implementation. This strategic win in the
Palatin Technologies’ (NYSE: PTN)* Oral MC4R Agonist Gets FDA Orphan Drug Status; Phase 2 Results in Drug Targeting $44 Billion Obesity Market Expected Any Day According to the Company, alongside results from ulcerative colitis trial; Only Oral Option in Market Currently Dominated by Injections Uniquely Positioning Palatin; In an exciting
* PolyPid (NASDAQ: $PYPD) just completed enrollment in its pivotal Phase 3 trial with FDA Fast-Track status * Targeting the massive $10B surgical infection market * Wall Street analyst project 300%+ potential gains PolyPid (Nasdaq: PYPD), an under-the-radar medical innovator trading at just $2.74 per share, just announced a
This Article Contains Promotional Content on behalf of Beyond Oil. In a market where institutional capital is scarce for small-cap companies, Beyond Oil Ltd.* (CSE: BOIL | OTCQB: BEOLF | Frankfurt: UH9) has achieved what few can—securing a C$10.5 million strategic investment from Clal Financial Management, a subsidiary
DarioHealth Corp. (Nasdaq: DRIO)* announced its fourth quarter and full-year 2024 financial results today, surpassing analyst expectations and demonstrating remarkable growth in its business-to-business-to-consumer (B2B2C) segment. The digital health company, which specializes in AI-driven chronic condition management, reported Q4 revenue of $7.6 million,
This Article Contains Promotional Content on behalf of Beyond Oil. In a significant move for the food-tech sector, Beyond Oil Ltd. has received global supplier approval from Restaurant Brands International (RBI), allowing its patented oil filtration system to be offered through more than 30,000 franchise locations of Burger
A newly published study from the Cleveland Clinic’s Lerner Research Institute has added to the growing body of evidence supporting Nuvectis Pharma’s (NASDAQ: NVCT)* NXP900, a novel SRC/YES1 kinase inhibitor. The study, featured in Molecular Cancer Research, demonstrated that the combination of NXP900 with AstraZeneca’s blockbuster
This Article Contains Promotional Content on behalf of Beyond Oil. Laurel Eastman believes an Israeli innovation could dramatically improve food safety in the U.S. and is pushing for its widespread adoption. As the president of Latitude and a former senior advisor to Donald Trump, Eastman is determined to see
